The annual meeting of the American Association for Cancer Research, which convenes in San Diego on April 5, is viewed by most drug-industry watchers as a second-tier medical conference. But physicians and investors will be watching closely this year, as Pfizer will report on a drug that could dramatically extend the lives of patients with breast cancer. Pfizer’s (PFE) palbociclib is the first in a new class of cancer drugs called CDK 4/6
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it’s bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH, afflicts as much as 10% of U.S. adults, but most don’t realize it. It’s completely unrelated to viral hepatitis, but they share the name because of the shared symptom of inflamed liver. “Steato” means
TripAdvisor is finding that it’s good to make good on promises. The latest data from the world’s largest provider of travel reviews show that the fallout from a major change to its business model is abating and the path toward growth seems clear. This was a highlight of the company’s Q4 results on Feb 11. For more than a year, TripAdvisor (TRIP) has been shifting to a so-called metasearch business model. Its site lets users directly book hotels,